Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.

You may also be interested in...



Third Time’s A Charm? Endo’s Injectable Testosterone Finally Ready For Advisory Cmte.

FDA says reports of oil embolism and anaphylactic reations with other testosterone injectables also will be part of the discussion during an April 18 meeting of the Reproductive Health Drugs and Drug Safety and Risk Management advisory committees to review Aveed (testosterone undecanoate).

Endo Launches Fortesta, Raises 2011 Guidance

Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.

Endo Launches Fortesta, Raises 2011 Guidance

Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.

Related Content

Topics

UsernamePublicRestriction

Register

PS071763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel